/term/gross-profit-to-asset/TSE:4583 Chiome Bioscience (TSE:4583) Gross-Profit-to-Asset %
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Gross-Profit-to-Asset %

Chiome Bioscience (TSE:4583) Gross-Profit-to-Asset % : 13.01% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Chiome Bioscience's annualized Gross Profit for the quarter that ended in Mar. 2024 was 円228.0 Mil. Chiome Bioscience's average Total Assets over the quarter that ended in Mar. 2024 was 円1,752.7 Mil. Therefore, Chiome Bioscience's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 13.01%.

Chiome Bioscience Gross-Profit-to-Asset % Historical Data

The historical data trend for Chiome Bioscience's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Gross-Profit-to-Asset % Chart

Chiome Bioscience Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.10 7.78 14.48 15.32 20.10

Chiome Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.84 23.92 22.90 20.89 13.01

Competitive Comparison of Chiome Bioscience's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Chiome Bioscience's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chiome Bioscience's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's Gross-Profit-to-Asset % falls into.


Chiome Bioscience Gross-Profit-to-Asset % Calculation

Chiome Bioscience's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=398.595/( (2215.47+1751.454)/ 2 )
=398.595/1983.462
=20.10 %

Chiome Bioscience's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=227.992/( (1751.454+1753.934)/ 2 )
=227.992/1752.694
=13.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Chiome Bioscience Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Chiome Bioscience (TSE:4583) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Gross-Profit-to-Asset %
Comparable Companies
TSE:4564 TSE:2385 TSE:4594 TSE:2342 TSE:4591 TSE:4570 TSE:4576 TSE:4584 TSE:4896 TSE:4596 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071
Website
http://www.chiome.co.jp
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience (TSE:4583) Headlines

No Headlines